This is a working overview of chain of custody, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized peptide powder form |
| Solubility | Soluble in aqueous buffer | Dissolves in water and buffered saline |
| Typical storage temperature | 2 to 8 degrees Celsius | Refrigerated; protect from freezing and light |
| Common analytical method | Reversed-phase HPLC | Purity and related substances |
| Mass confirmation | Electrospray mass spectrometry | Verifies approximately 4,813 Da |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
=== Contestants === 1st - Jasmin Bell, Pastry Instructor from Seattle, Washington 2nd - Jonathan Elias, Pastry Chef from Troy, Michigan 3rd - Jessica Scott, Executive Pastry Chef from San Diego, California 4th - Ray Vizcaino, Cake Decorator from San Diego, California 5th - Tyler Davis, Pastry Chef from St. Louis, Missouri 6th - Dina Melendez, Pastry Chef from Brooklyn, New York 7th - Cliff Butler, Pastry Chef from Austin, Texas 8th - Andrea Kratville, Home Baker from Sonora, California
The outer area of the upper arm. The abdomen, avoiding a 2-inch circle around the navel. The front of the thigh, between 4 inches from the top of the thigh and 4 inches above the knee. The upper back. The upper area of the buttock, just behind the hip bone. The choice of specific injection site is based on the medication being administered, with heparin almost always being administered in the abdomen, as well as preference. Injections administered frequently or repeatedly should be administered in a different location each time, either within the same general site or a different site, but at least one inch away from recent injections.
The Albert Einstein College of Medicine is a private medical school in New York City. Founded in 1953, Einstein is an independent degree-granting institution within the Montefiore Einstein Health System. Einstein hosts MD, PhD, and master's programs. Admission to its MD program is highly selective, with an acceptance rate of 1.85% in 2024. Joint masters are offered with the City University of New York and Yeshiva University's Cardozo School of Law. Einstein is also home to one of the first three Medical Scientist Training Programs inaugurated in 1964. This joint MD/PhD program has received continuous funding from the National Institutes of Health. Planning for the college was initiated by Yeshiva University President Samuel Belkin in 1945. Physicist Albert Einstein, who noted that the college would be unique as it would provide medical training to "students of all creeds and races", lent his name to the institution. Due to Yeshiva's financial difficulties, Einstein was transferred to Montefiore in 2015. Following a $1 billion donation to the school by Ruth Gottesman in 2024, Einstein became tuition-free for all MD students. Einstein houses several NIH-designated centers and has contributed to major medical advances, including the first coronary artery bypass surgery. Faculty members have included 18 members of the National Academy of Sciences, three National Medal of Science recipients, and neurologist and writer Oliver Sacks.
Sources: en.wikipedia.org
Several times during the 1970s and 1980s, Detroit was named the "arson capital of America", and the city was also repeatedly dubbed the "murder capital of America". Detroit was frequently listed by FBI crime statistics as the "most dangerous city in America" during this time frame. Crime rates in Detroit peaked in 1991 at more than 2,700 violent crimes per 100,000 people. Population decline left abandoned buildings behind that became magnets for the drug trade, arson, and other criminal activity. The city's criminality has pushed tourism away from the city, and several foreign countries even issued travel warnings for the city. Around this period, in the days of the year preceding and including Halloween, Detroit citizens went on a rampage called "Devil's Night". A tradition of light-hearted minor vandalism, such as soaping windows, had emerged in the 1930s, but by the 1980s, it had become, said Mayor Young, "a vision from hell." During the height of the drug era, Detroit residents routinely set fire to houses that were known as popular drug-dealing locations, accusing the city's police of being either unwilling or unable to solve the deep problems of the city. The arson primarily occurred in the inner city, but surrounding suburbs were also often affected. The crimes became increasingly destructive throughout this period. Over 800 fires were set, mostly to vacant houses, in the peak year of 1984, overwhelming the city's fire department.
== Institutions with hypobaric chambers == terraXcube, Eurac Research, accredited laboratory for environmental testing with large climatic chambers and medical clinic Centro de Medicina Aeroespacial de la Fuerza Aerea Colombiana, Aviation medicine, physiological, and hypobaric services Royal New Zealand Air Force Aviation Medicine Unit , Aviation medicine training and hypobaric services U.S. Army Institute of Environmental Medicine, Natick, MA, 33 years experience with its Hypobaric Chamber Facility Sheppard Air Force Base in Wichita Falls, Texas University of North Dakota's John D. Odegard School of Aerospace Sciences, Aviation Training Naval Operational Medicine Institute, Operational medical and survival training and consultative services to military forces worldwide Arizona State University Polytechnic Campus, Aircrew training, research, and other uses National AeroSpace Training And Research (NASTAR) Center South, Air and space training, research, and education RAF Centre of Aviation Medicine Center for Man in Aviation, Royal Netherlands Air Force, Aircrew training, physiology, research and certification of equipment University Hospitals Cleveland Medical Center in Cleveland, Ohio, aerospace physiology research AXA Training Center, Training ground of Liverpool F.C.
In enzymology, cholestenone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes several chemical reactions of steroids in which a cholest-4-en-3-one is converted to the corresponding 5α-dihydrocholestan-3-one. For example, 5α-dihydroprogesterone is the product of the reduction of progesterone:
=== Stable interactions vs. transient interactions === Stable interactions involve proteins that interact for a long time, taking part of permanent complexes as subunits, in order to carry out functional roles. These are usually the case of homo-oligomers (e.g. cytochrome c), and some hetero-oligomeric proteins, as the subunits of ATPase. On the other hand, a protein may interact briefly and in a reversible manner with other proteins in only certain cellular contexts – cell type, cell cycle stage, external factors, presence of other binding proteins, etc. – as it happens with most of the proteins involved in biochemical cascades. These are called transient interactions. For example, some G protein–coupled receptors only transiently bind to Gi/o proteins when they are activated by extracellular ligands, while some Gq-coupled receptors, such as muscarinic receptor M3, pre-couple with Gq proteins prior to the receptor-ligand binding. Interactions between intrinsically disordered protein regions to globular protein domains (i.e. MoRFs) are transient interactions.
Sources: en.wikipedia.org
=== EC 1.5.1 With NAD+ or NADP+ as acceptor === EC 1.5.1.1: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NAD(P)H) EC 1.5.1.2: pyrroline-5-carboxylate reductase EC 1.5.1.3: dihydrofolate reductase EC 1.5.1.4: Now included with EC 1.5.1.3 dihydrofolate reductase EC 1.5.1.5: methylenetetrahydrofolate dehydrogenase (NADP+) EC 1.5.1.6: formyltetrahydrofolate dehydrogenase EC 1.5.1.7: saccharopine dehydrogenase (NAD+, L-lysine-forming) EC 1.5.1.8: saccharopine dehydrogenase (NADP+, L-lysine-forming) EC 1.5.1.9: saccharopine dehydrogenase (NAD+, L-glutamate-forming) EC 1.5.1.10: saccharopine dehydrogenase (NADP+, L-glutamate-forming) EC 1.5.1.11: D-octopine dehydrogenase EC 1.5.1.12: Now EC 1.2.1.88, L-glutamate γ-semialdehyde dehydrogenase EC 1.5.1.13: Now EC 1.17.1.5, nicotinate dehydrogenase EC 1.5.1.14: Now included with EC 1.5.1.21 Δ1-piperideine-2-carboxylate reductase EC 1.5.1.15: methylenetetrahydrofolate dehydrogenase (NAD+) EC 1.5.1.16: D-lysopine dehydrogenase EC 1.5.1.17: alanopine dehydrogenase EC 1.5.1.18: ephedrine dehydrogenase EC 1.5.1.19: D-nopaline dehydrogenase EC 1.5.1.20: methylenetetrahydrofolate reductase (NAD(P)H) EC 1.5.1.21: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NADPH) EC 1.5.1.22: strombine dehydrogenase EC 1.5.1.23: tauropine dehydrogenase EC 1.5.1.24: N5-(carboxyethyl)ornithine synthase EC 1.5.1.25: thiomorpholine-carboxylate dehydrogenase EC 1.5.1.26: β-alanopine dehydrogenase EC 1.5.1.27: 1,2-dehydroreticulinium reductase (NADPH) EC 1.5.1.28: opine dehydrogenase EC 1.5.1.29: Now covered by EC 1.5.1.38 [FMN reductase (NADPH)], EC 1.5.1.39 [FMN reductase [NAD(P)H])] and EC 1.5.1.41 (riboflavin reductase [NAD(P)H]) EC 1.5.1.30: flavin reductase (NADPH) EC 1.5.1.31: berberine reductase EC 1.5.1.32: vomilenine reductase EC 1.5.1.33: pteridine reductase EC 1.5.1.34: 6,7-dihydropteridine reductase EC 1.5.1.35: identical to EC 1.2.1.19, aminobutyraldehyde dehydrogenase, as the substrates 1-pyrroline and 4-aminobutanal are interconvertible EC 1.5.1.36: flavin reductase (NADH) EC 1.5.1.37: FAD reductase (NADH) EC 1.5.1.38: FMN reductase (NADPH) EC 1.5.1.39: FMN reductase (NAD(P)H) EC 1.5.1.40: 8-hydroxy-5-deazaflavin:NADPH oxidoreductase EC 1.5.1.41: riboflavin reductase (NAD(P)H) EC 1.5.1.42: FMN reductase (NADH) EC 1.5.1.43: carboxynorspermidine synthase EC 1.5.1.44: festuclavine dehydrogenase EC 1.5.1.45: FAD reductase (NAD(P)H) EC 1.5.1.46: agroclavine dehydrogenase EC 1.5.1.47: dihydromethanopterin reductase [NAD(P)+] EC 1.5.1.48: 2-methyl-1-pyrroline reductase EC 1.5.1.49: 1-pyrroline-2-carboxylate reductase [NAD(P)H] EC 1.5.1.50: dihydromonapterin reductase EC 1.5.1.51: N-[(2S)-2-amino-2-carboxyethyl]-L-lutamate dehydrogenase EC 1.5.1.52: staphylopine dehydrogenase EC 1.5.1.53: methylenetetrahydrofolate reductase (NADPH) EC 1.5.1.54: methylenetetrahydrofolate reductase (NADH)
=== Regional groups === Head and neck – includes everything above the thoracic inlet Upper limb – includes the hand, wrist, forearm, elbow, arm, shoulder Thorax – the region of the chest from the thoracic inlet to the thoracic diaphragm Human abdomen to the pelvic brim or to the pelvic inlet The back – the spine and its components, the vertebrae, sacrum, coccyx, intervertebral disks Pelvis and perineum – the pelvis consists of everything from the pelvic inlet to the pelvic diaphragm; the perineum is the region between the sex organs and the anus Lower limb – everything below the inguinal ligament, including the hip, the thigh, the knee, the leg, the ankle, the foot
==== Adsorption ==== Adsorption is a mass transfer process in which a substance is transported from the liquid phase to the surface of a solid/liquid (adsorbent) and becomes physically and chemically bonded (adsorbate). Adsorption can be classified into two forms based on the type of attraction between the adsorbate and the adsorbent: physical and chemical adsorption, commonly known as physisorption and chemisorptions.
Sources: en.wikipedia.org
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.
Mass spectrometry establishes the molecular mass and can detect sequence variants. Reversed-phase chromatography assesses purity and related substances. Peptide mapping after digestion confirms the amino acid sequence itself.
Typical fields include appearance, purity by chromatographic area, mass confirmation, and water or counterion content. Some documents also list residual solvents and microbial limits. The specific fields depend on the supplier and the intended application.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.